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Microwave (MW) irradiation allows to prepare a mini-library of
pyridophenoxazinone derivatives, that are crucial intermediates
in the synthesis of new antiproliferative compounds, active for
human lymphoma/leukemia. The optimized procedure, consist-
ing of a continuous input power of 50 W (80 8C) and a reaction
time of 30 min, leads in very satisfactory yields to both re-
gioisomers 5H-pyrido[2,3-a]phenoxazin-5-ones and isomeric
5H-pyrido[3,2-a]phenoxazin-5-ones, starting from readily avail-
able quinoline-5,8-dione and substituted 2-aminophenols
(APhOHs). Broad functional group tolerance was observed. The
availability of derivatives carrying a carboxyl group at the C-9
and C-10 positions enables the synthesis of a new family of 5H-
pyridophenoxazin-5-one conjugates that were shown to exhibit
good anti-cancer activity.
Pyridophenoxazinones (PPXZs) are four-annulated iminoqui-
none planar systems (Figure 1) that satisfy the structural re-
quirements of typical DNA-intercalating agents.[1] The DNA/
PPXZ complexes are stabilized by p-p stacking interactions be-
tween the aromatic bases guanine-cytosine and the electron-
poor iminoquinone system.[2,3] In addition, the iminoquinone
moiety exploits the well-known ability of the quinones to gen-
erate reactive oxygen species (ROS) by reversible oxidation-re-
duction cycles.[4, 5] To sum up, these features make the PPXZ-
based compounds attractive tools that perform their anti-
tumoral effect through different and concurrent mechanisms.[6]
Continuing our search for new potential anticancer drugs
derived from PPXZ,[7] on the basis of our previous studies of
molecular dynamics, compounds as 12 and 13 are expected to
inhibit topoisomerases I and II, enzymatic systems with major
modulating effects on DNA replication.
Indeed, molecular modelling suggests, that it is possible to
have an efficient inhibition of topoisomerases I and II[6b,8] if a
flexible hydrophilic moiety (such as polar amino acids, sugars,
diamines, etc.) is linked to the PPXZ ring.
In this paper we wish to report the synthesis of some PPXZ
derivatives carrying a carboxyl group at the C-9 and C-10 posi-
tion at the A ring (4 and 5, Figure 1) and their conjugate de-
rivatives (12 and 13, Figure 2).
The rational production of new substituted phenazine and
phenoxazinone scaffolds is highly desirable[9] and has been
mainly prevented by the absence of general methodologies for
the production of diversely substituted phenazines and phe-
noxazines.
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Figure 1. 5H-Pyrido[2,3-a]phenoxazin-5-one (a) and 5H-pyrido[3,2-a]phenox-
azin-5-one (b) derivatives.
Figure 2. 5H-Pyrido[2,3-a]phenoxazin-5-one (a) and 5H-pyrido[3,2-a]phenox-
azin-5-one (b) carboxyamide derivatives.
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The conventional synthetic method to prepare PPXZ de-
rivatives as 1–11, which involves the reaction of an equimolar
amount of quinoline-5,8-dione (QQ) and of substituted 2-ami-
nophenols (APhOHs) in refluxing glacial acetic acid for 24 h, is
not very effective owing to rather harsh reaction conditions
and produces the poorest yields. Several side products, like
phenoxazines (14), aminophenoxazin-3-ones (15), tripheno-
dioxazines (16), are reported[7a,e] to accompany the desired
PPXZs (Figure 3). A large amount of black, intractable polymeric
materials are also formed, thus decreasing significantly the
yields of PPXZs and also encumbering the subsequent purifica-
tion procedures of the final reaction mixtures.
Under the conditions mentioned above, QQ 17 (path A,
Scheme 1) reacts with the substituted benzoic acids (21 and
22, Table 1) affording the two regioisomeric [2,3-a] PPXZ de-
rivatives with yields of 2 and 3%, respectively.
Previous theoretical studies[7a] and synthetic experiments
suggested that the reaction yielding the [2,3-a] PPXZ system,
starts firstly with the attack of the nucleophilic amino group of
2-APhOH on the C-8 carbonyl group of QQ 17 and the reaction
proceeds towards the formation of the [2,3-a] PPXZ system
through a dehydration step followed by a intra-molecular Mi-
chael addition of the aminophenol hydroxyl group to the a,b-
unsatureted quinone system (path A, Scheme 1).
The [3,2-a] PPXZs formation is much less favoured than the
corresponding [2,3-a] one, therefore to obtain the former de-
rivative the C-8 carbonyl group of QQ 17 must become un-
available for the initial nucleophilic attack on the amino group,
and this is achieved by adding some M2+ salt such as Co(CH3
CO2)2 to the reaction mixture. The result is the chelation by the
metal ion of both nitrogen and C-8 oxygen atoms in QQ 17,
thus favouring a Michael addition of the nucleophilic amino
group at C-6 carbon atom that is alpha to C-5 carbonyl group.
Quinone reduction takes place and is followed by reoxidation
by oxygen or by the quinone present in situ. Subsequently, an
intramolecular attack of the hydroxyl group of aminophenol to
the carbonyl carbon in the C-5 position yields a hemiketal,
which undergoes a substitution reaction by the amino group of
second molecule of aminophenol (18) affording, after re-
arrangement, the [3,2-a] PPXZ compound (path B, Scheme 1).
Our first attempts to prepare compounds like 4a,b and
5a,b, exploiting the above procedures, starting from QQ and
amino phenols carrying a carboxyl group, were totally un-
successful and frustrating (cfr. Table 1). Several modifications of
the experimental conditions, aimed at overcoming the prob-
lems encountered, were examined with no significant improve-
ments.
Under these circumstances, we considered it worthwhile to
report a new microwave (MW) assisted[10] simple and con-
venient synthetic procedure to obtain pyridophenoxazinones
with high yields, very short reaction times and, most im-
portantly, a drastically diminished production of black poly-
meric residues.
Therefore, a representative reaction where QQ 17 was com-
bined with 2-aminophenol 19, was carried out in microwave re-
actor DISCOUVER type from CEM company by varying the vol-
umes of the solution (between 1 and 5 mL), and the ratio of
substrates, microwave time (from 5 to 120 min) as well as pow-
er (80 8C internal probe, in the range 50–300 W). A continuous
input power of 50 W and a reaction time of 30 min were found
to give a very satisfactory yield (Table 1). The highest pressure
achieved inside the probe was 16 PSI (1100 mbar).
The optimized procedure was then applied to miscella-
neous 4- and 5-substitued 2-aminophenols (20-29) dissolved
either in plain glacial acetic acid or in glacial acetic acid con-
Figure 3. Side products obtained during the synthesis of PPXZs.
Scheme 1. Synthesis of substituted 5H-pyrido[2,3-a]phenoxazin-5-ones and
of isomeric 5H-pyrido[3,2-a]phenoxazin-5-ones.
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taining cobalt acetate in a stoppered glass tube. The glacial
acetic acid was used as reaction medium because it represents
a good compromise between the necessity of the carbonyl ac-
tivation and the over-deactivation of the amine nucleophilicity.
The results reported in Table 1 (A vs A+MW and B vs B+
MW) show clearly how the use of microwave heating leads to
significant increases of the yields in all the cases investigated.
In particular, it is noteworthy that APhOHs 22 and 23 gave the
corresponding desired products (4a,b and 5a,b) that could not
be obtained at all by the classical synthetic procedures. All the
evidence suggests that, under MW irradiation, the reaction pro-
ceeds by the same route followed under the conventional
heating and that the MW probably helps the crucial step of de-
hydration (Scheme 1).
With the availability of such compounds we explored the
coupling of PPXZ derivative 4a under standard conditions with
properly protected sugar derivative 30.[11,12] After removal of
the acetyl protecting groups the final product 32 was obtained
with overall yields of 63%. Likewise the coupling of the de-
rivative 4a was performed under the above conditions with the
N1,N1-dimethylethane-1,2-diamine obtaining the product 33 in
81% yields (Scheme 2). Both compounds, 32 and 33, are cur-
rently under biological evaluation on human liquid- and solid-
tumour cell lines.
In conclusion, we have proved that the use of microwave
heating in the synthesis of the pyridophenoxazinone de-
rivatives represents a sound innovation from a preparative
point of view. To our knowledge this reaction represents a per-
fect starting point to expand the chemistry of iminoquinones
as lead compounds for anticancer drugs. Finally, these results in
addition to the ease of use, safety and rapid heating confirm
microwaves as an attractive tool for synthetic chemistry as
compared to conventional methods.
Supporting Information available: Experimental procedures
and characterization data of 26 compounds, 1H and 13CNMR.
Table 1. Comparison of yields and reaction times under classical (A and B) and microwave (A+MW and B+MW) assisted conditions for the synthesis of
miscellaneous 5H-pyridophenoxazinones 1a and 1b.
2-PhOHs Pathway[a] [2,3-a] (%) [3,2-a] (%) 2-PhOHs Pathway[a] [2,3-a] (%) [3,2-a] (%)
A 12 3 A 4 2
B 1 35 B >1 15
A+MW 78 8 A+MW 65 3
B+MW 4 88 B+MW 7 71
A 7 4 A 13 >1
B 3 30 B 1 26
A+MW 59 10 A+MW 78 14
B+MW 4 65 B+MW 4 87
A 5 2 A 11 1
B 4 20 B 2 28
A+MW 41 7 A+MW 71 21
B+MW 3 54 B+MW 8 88
A 2 0 A 10 1
B 0 >1 B 1 13
A+MW 50 0 A+MW 58 15
B+MW 1 50 B+MW 3 60
A 3 0 A 9 >1
B 0 1 B 1 23
A+MW 60 2 A+MW 70 13





[a] Pathway A: QQ and 2-APhOH (1:1), glacial acetic acid, 24 h, reflux; Pathway B: QQ, 2-APhOH, and Co2+ (1:1:1), glacial acetic acid, 24 h, reflux; Pathway
A+MW: QQ and 2-APhOH (1:1), glacial acetic acid, 80 8C (50 W), 30 min; Pathway B+MW: QQ, 2-APhOH, and Co2+ (1:1:1), glacial acetic acid, 80 8C (50 W),
30 min.
Scheme 2. Synthesis of new conjugate derivatives 32 and 33.
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